Effect of various treatments on unidirectional secretory,unidirectional reabsorptive and net urate fluxes by chick PTCs
| Treatment . | N . | Side . | Nonspecific . | Secretory . | Reabsorptive . | Net . |
|---|---|---|---|---|---|---|
| Control | 3 | 100 | 34±5.9 | 65±5.9 | ||
| K+ (30 mmol l-1) | 3 | L | ↓TER | 133±19.2 | 59±13.3 | 73±17.3 |
| Control | 3 | 100 | 34±4.9 | 65±4.9 | ||
| Glucose-free | 3 | L | ↓Iglu | 116±15.9 | 36±4.8 | 80±13.6 |
| Control | 3 | 100 | 34±7.3 | 65±7.4 | ||
| Cl- free | 3 | L | No | 89±15.3 | 44±11.3 | 45±16.0 |
| Control | 3 | 100 | 33±7.4 | 67±7.4 | ||
| pH 7.7 | 3 | L | ↓Iglu | 125±17.2 | 49±14.9 | 75±5.6 |
| Control | 3 | 100 | 34±7.6 | 66±7.6 | ||
| Oxonic acid (2.5 mmol l-1) | 3 | L | No | 98±3.4 | 41±7.4 | 57±4.2 |
| Control | 3 | 100 | 33±6.2 | 66±6.2 | ||
| Pyrazine (2 mmol l-1) | 3 | L | No | 123±18.2 | 44±14.6 | 78±32.4 |
| Control | 4 | 100 | 31±4.2 | 68±4.2 | ||
| Adenosine (2 mmol l-1) | 4 | L | No | 112±15.7 | 39±11.0 | 72±18.6 |
| Control | 5 | 100 | 31±4.8 | 68±4.8 | ||
| Nicotinic acid (0.3 mmol l-1) | 5 | L | No | 82±8.4 | 34±7.6 | 48±15.3 |
| Control | 5 | 100 | 36±9.0 | 63±9.0 | ||
| Nocodozole (0.03 mmol l-1) | 5 | Both | ↓Iglu | 114±27.4 | 70±21.5* | 44±8.5 |
| Control | 4 | 100 | 28±5.3 | 71±5.3 | ||
| Cytochalsin D (10-3 mmol l-1) | 4 | Both | ↓TER | 124±15.3 | 120±38.9* | 4±23.8* |
| Treatment . | N . | Side . | Nonspecific . | Secretory . | Reabsorptive . | Net . |
|---|---|---|---|---|---|---|
| Control | 3 | 100 | 34±5.9 | 65±5.9 | ||
| K+ (30 mmol l-1) | 3 | L | ↓TER | 133±19.2 | 59±13.3 | 73±17.3 |
| Control | 3 | 100 | 34±4.9 | 65±4.9 | ||
| Glucose-free | 3 | L | ↓Iglu | 116±15.9 | 36±4.8 | 80±13.6 |
| Control | 3 | 100 | 34±7.3 | 65±7.4 | ||
| Cl- free | 3 | L | No | 89±15.3 | 44±11.3 | 45±16.0 |
| Control | 3 | 100 | 33±7.4 | 67±7.4 | ||
| pH 7.7 | 3 | L | ↓Iglu | 125±17.2 | 49±14.9 | 75±5.6 |
| Control | 3 | 100 | 34±7.6 | 66±7.6 | ||
| Oxonic acid (2.5 mmol l-1) | 3 | L | No | 98±3.4 | 41±7.4 | 57±4.2 |
| Control | 3 | 100 | 33±6.2 | 66±6.2 | ||
| Pyrazine (2 mmol l-1) | 3 | L | No | 123±18.2 | 44±14.6 | 78±32.4 |
| Control | 4 | 100 | 31±4.2 | 68±4.2 | ||
| Adenosine (2 mmol l-1) | 4 | L | No | 112±15.7 | 39±11.0 | 72±18.6 |
| Control | 5 | 100 | 31±4.8 | 68±4.8 | ||
| Nicotinic acid (0.3 mmol l-1) | 5 | L | No | 82±8.4 | 34±7.6 | 48±15.3 |
| Control | 5 | 100 | 36±9.0 | 63±9.0 | ||
| Nocodozole (0.03 mmol l-1) | 5 | Both | ↓Iglu | 114±27.4 | 70±21.5* | 44±8.5 |
| Control | 4 | 100 | 28±5.3 | 71±5.3 | ||
| Cytochalsin D (10-3 mmol l-1) | 4 | Both | ↓TER | 124±15.3 | 120±38.9* | 4±23.8* |
Data are presented as a percentage of the paired control secretory flux and are means ± s.e.m. (N=the number of preparations). The treatments were administered to the luminal side of the epithelium alone(L) or both the interstitial and luminal sides of the epithelium (both). Transepithelial resistance (TER) and phlorizin-sensitive glucose current(Iglu), measures of proximal tubule-like function and tissue viability, were monitored to determine if treatments were nonspecific. No effect of the treatment on TER or Iglu (No). ↓TER and ↓Iglu indicate a decrease in transepithelial resistance and phlorizin-sensitive glucose current, respectively(P<0.05, paired t-test).
Significantly different from paired control, P<0.05, paired t-test